Franco Iuliano

Learn More
Imatinib mesylate has become the treatment of choice for chronic myeloid leukemia (CML): the standard dose for chronic- phase (CP) CML is 400 mg daily. Response rates are different according to Sokal score, being significantly lower in intermediate and high Sokal risk patients. Phase 1 and 2 trials have shown a dose-response effect and high-dose imatinib(More)
To assess the effect of age on response and compliance to treatment in patients with chronic myeloid leukemia (CML) we performed a sub-analysis within a phase II trial of the GIMEMA CML Working Party (CML/002/STI571). Since the WHO cut-off age to define an older patient is 65 years, among the 284 patients considered, we identified 226 (80%) younger patients(More)
1Institute of Hematology L. & A. Seràgnoli, University of Bologna, Bologna; 2Department of Hematology, University La Sapienza Rome, Rome; 3Department of Internal Medicine, S. Luigi Gonzaga Hospital Orbassano, Torino; 4Department of Hematology, University of Catania, Catania; 5Department of Hematology, University of Bari, Bari; 6Division of Hematology,(More)
  • 1